Drug Development
European phase III trial for Miraxion in Huntington disease commences
Published in Medical Letter on the CDC and FDA, January 15th, 2006
The U.S. phase III clinical trial of Miraxion in Huntington disease commenced dosing in September, 2005.
Rick Stewart, CEO of Amarin, commented: "The commencement of the 240 patient European phase III clinical trial in Huntington's disease is a major milestone for Amarin. The U.S. trial of 300 patients is now well underway and we expect the European trial will show similar positive progress as patient enrollment accelerates."
Miraxion has Orphan Drug designation in the U.S. and in Europe. Additionally,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Amebiasis Diagnosis
Report compares real-time PCR protocols for differential diagnosis of amebiasis - Hemophilia Epidemiology
Report reviews demographics of hemophilia in developing countries - Streptococcus Epidemiology
Clonal association found between Streptococcus pneumoniae serotypes 23A and 23F - Vaccine Efficacy
Hepatitis A immunization program aimed at child-care centers proves successful - Acute Lymphoblastic Leukemia
European study confirms efficacy of clofarabine in pediatric patients with ALL - Acute Peripheral Arterial Occlusion
U.S. FDA specifies protocol for phase III trial of novel arterial perfusion with alfimeprase-3 - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
